Best Lentiviral Vector CDMOs in Asia

← All Lentiviral CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
9
CDMOs tracked
7
Fully scored
3
With FDA records
8
FDA inspections
23
EMA/MHRA GMP certs

For Asia-manufactured lentiviral vector programs, Pharmaron Biologics, AGC Biologics, and Genezen lead CDMO Signal's ranking of lentiviral vector CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 37 scored lentiviral vector CDMOs to 7 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Lentiviral vectors are the workhorse of ex vivo gene therapy, used to engineer T cells for CAR-T and to modify hematopoietic stem cells. Because the vector ends up in patient-bound cells, manufacturers carry the regulatory weight of a critical starting material under full GMP.

Choosing a lentiviral vector CDMO comes down to BSL-2 containment, a mature suspension or adherent platform, robust analytics (titer, potency, RCL testing), and a clean regulatory record. The rankings below score each CDMO on FDA inspection history, GMP certification, clinical-program activity, and capacity signals.

FDA inspection outcomes across these CDMOs: 5 NAI (no action), 3 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), United States (8), Germany (3), Italy (2).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
 86.9 100.0 3 insp · 0 GMP Available 0 programs
2
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
3
GZ
Genezen
Indianapolis, IN · Lexington, MA
 70.7 84.1 3 insp · 0 GMP Available 0 programs
4
IU
Indiana University Vector Production Facility
Indianapolis, IN
 66.2 — — — 47 programs
5
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
 60.5 — — — 0 programs
6
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
 60.0 — — Limited 0 programs
7
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
 59.5 — — — 8 programs
—
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
 Profiled — — — 0 programs
—
Canton Biologics
Guangzhou, China
 Profiled — — — 0 programs
How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Pharmaron Biologics, AGC Biologics, Genezen. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 3 Lentiviral Vector CDMOs with FDA inspection records and 23 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities
Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC